[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hiv-treatment\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hiv-treatment":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100468773","implementation-trial-to-evaluate-a-population-health-combination-intervention-to-meet-hiv-testing-linkage-and-viral-suppression-goals-in-alabama-100468773",false,"NCT05384145","Implementation Trial to Evaluate a Population Health Combination Intervention to Meet HIV Testing, Linkage, and Viral Suppression Goals in Alabama","A Type 2 Hybrid Effectiveness-implementation Trial to Evaluate a Population Health Combination Intervention to Meet HIV Testing, Linkage, and Viral Suppression Goals in Coastal Alabama","COAST-AL","Inclusion Criteria:\n\n* AIM 1 \\& 3:\n* Fit into one of the following categories:\n\n  1\\) MCHD leadership, 2) ADPH leadership, 3) clinic administrators, 4) outreach testing specialists, 5) linkage coordinators and community health workers, 6) physicians, 7) nurses, 8) counselors all working at HIV care facilities in the six MCHD jurisdiction counties.\n* Over the age of 18 years old.\n\nAIM 2: (IDIs)\n\n* Over the age of 13 years old\n* Tested for HIV in MCHD jurisdiction from time of COASTAL implementation to 36 months post-implementation start date.\n\nExclusion Criteria:\n\n* Exclusion criteria include unwillingness or inability to provide informed consent.",true,"ALL","13 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this study is to adapt and evaluate a combination intervention that includes: (1) a data-driven approach to directed community-based HIV testing to areas with high need, (2) Project Connect to expedite linkage to care at time of diagnosis, (3) and a Rapid ART (antiretroviral therapy)Start program, all in Mobile County Health Department (MCHD) jurisdictions in Alabama.",[28,29,30,31],"HIV","HIV Linkage to Care","HIV Testing","HIV Treatment","RECRUITING","2026-05-13",{"date":35,"type":36},"2026-05-18","ACTUAL",{"date":38,"type":36},"2024-03-27",{"date":40,"type":22},"2027-05-31",{"name":42,"class":43},"University of Alabama at Birmingham","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":44},"100437703","hiv-outpatient-monitoring-evaluation-through-self-collection-of-dried-blood-spots-100437703","NCT04979728","HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots","HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots (HOME-1)","HOME-1","Inclusion criteria:\n\n* ≥18 years old\n* Receiving one or more antivirals for HIV treatment or prevention. This may include TFV (as TDF or TAF) and FTC (or 3TC)-based, LA (e.g., LA IM CAB±RPV Q4W or Q8W), or other antivirals (those who are transitioning to LA antivirals \\[e.g., LA IM CAB±RPV Q4W or Q8W\\] will also be eligible)\n* Current patient at the UCH-IDGP clinic\n* Able to comply with study procedures, including directly observed self-collection of DBS by fingerstick, Tasso-M20\u002FTasso+, Mitra, and\u002For other self-collection methods\u002Fdevices, and completion of survey\n\nExclusion criteria:\n\n* Inability to provide informed consent\n* Unable or unwilling to comply with directly observed self-collection of DBS (e.g., unavailable or unable to use live video-streaming or time-stamped video recording technology)\n* Any uncontrolled medical, social, or mental health issue(s) that, in the opinion of the investigators, could interfere with the study participation or study outcomes (e.g., current incarceration)\n* Any medical condition that, in the opinion of the study team, acutely and\u002For transiently influences the PK of CAB±RPV, including acute kidney injury, hepatic insufficiency, significant drug-drug interactions, active hemolysis or symptomatic hemoglobinopathies, etc. (Note: Given the need for PK data in pregnancy, women who become pregnant while on LA IM CAB±RPV Q4W or Q8W will be allowed to participate in this study, if their clinical provider decides to continue this regimen.)","18 Years",{"count":55,"type":22},150,"OBSERVATIONAL","The goal of this observational study is to establish an operational framework for home self-collections of blood samples to be used for antiviral drug concentration measurements.\n\nParticipants will continue on their prescribed antiviral(s) for HIV treatment or prevention and followed for up to approximately 1 year. The investigators will compare drug concentrations of antivirals and relevant metabolites\u002Fanabolites in clinic-collected and self-collected blood samples.",[31,59],"HIV Prevention",[61,62,63,64,65,66,67,68,69,70,71],"antivirals","ART","PrEP","long-acting","cabotegravir","rilpivirine","tenofovir","lenacapavir","self-collections","self-collected blood samples","drug concentrations","2026-02-27",{"date":74,"type":36},"2026-03-03",{"date":76,"type":36},"2021-05-27",{"date":78,"type":22},"2027-06-30",{"name":80,"class":43},"University of Colorado, Denver",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":18,"minAge":53,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":92,"conditions":93,"keywords":97,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":44},"100567451","enhancing-hiv-prevention-and-reducing-alcohol-use-among-people-receiving-sti-care-in-lilongwe-malawi-100567451","NCT06668363","Enhancing HIV Prevention and Reducing Alcohol Use Among People Receiving STI Care in Lilongwe, Malawi","Enhancing HIV Prevention and Reducing Alcohol Use Among People Receiving STI Care in Lilongwe, Malawi: A Pilot Implementation Study","Treat4All","Inclusion Criteria:\n\n* Men and women age 18 years or older.\n* Receiving care at Bwaila STI clinic.\n* Report recent heavy drinking (greater than or equal to 4 drinks a day in the past 30 days for men and greater than or equal to 3 drinks a day in the past 30 days for women\n* Willing to receive an HIV test at study enrollment, if not previously diagnosed Report not taking ART, recent suboptimal adherence to ART, or recent history of unsuppressed HIV viral load \\[for PWH\\] or no recent oral PrEP use (self-reported taking no PrEP pills in past 7 days) \\[for those at risk of HIV\\]\n* Plan to reside in the Lilongwe area for at least 6 months.\n* Not participating in other HIV or alcohol programs\n* Ability and willingness of participant to provide informed consent.\n* Willingness to provide contact\u002Flocator information to be contacted for follow up study activities.\n\nExclusion Criteria:\n\n* Unable to participate in study activities due to psychological disturbance, cognitive impairment, or threatening behavior\n* Pregnant or breastfeeding\n* At risk of experiencing alcohol-related withdrawal symptoms\n* Acute physical or mental illness, including suicidal thoughts or behaviors\n* Participating in in other HIV or alcohol programs\n* Active drug dependence that would interfere with adherence to study requirements.\n* History of using injectible PrEP\n* Any other condition that in the opinion of the study investigator would compromise the safety of the study participant or study staff or would prevent proper conduct of the study.",{"count":90,"type":22},160,[25],"Purpose: To evaluate short-term efficacy and implementation of Treat4All, an alcohol reduction evidence-based intervention, for decreasing heavy drinking and optimizing HIV outcomes (viral suppression among People with HIV (PWH); Pre-exposure prophylaxis (PrEP) use among those at high risk of HIV)\n\nParticipants: Approximately 160 participants aged 18 years or older will be enrolled into this study.\n\nEligible participants will be recruited from two groups of individuals:\n\nPersons at risk of HIV: Individuals receiving (STI) care who report recent heavy drinking (n=80) and no recent use of PrEP. Persons with HIV: Individuals with HIV who report recent heavy drinking and either a history of unsuppressed viral load or recent suboptimal adherence to ART (n=80).\n\nProcedures (methods): Pilot two-arm randomized controlled trial (1:1; Treat4All Intervention vs Usual Care)",[94,95,96,59,31],"Alcohol Consumption","PrEP Uptake","Recent Heavy Drinking",[63,28,59,98,99],"Alcohol reduction","Alcohol","2026-01-28",{"date":102,"type":36},"2026-01-30",{"date":104,"type":36},"2024-12-12",{"date":106,"type":22},"2026-06",{"name":108,"class":43},"University of North Carolina, Chapel Hill"]